Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.
The pharmacokinetics of chlormethiazole were studied in eight patients with advanced cirrhosis of the liver and in six healthy volunteers after oral and intravenous administration of the drug. In the patients the systemic bioavailability of oral chlormethiazole was increased about tenfold, whereas its elimination was only slightly retarded. The increased bioavailability was clearly due to decreased first-pass metabolism of chlormethiazole in the cirrhotic liver. The results indicate that chlormethiazole should be used in reduced dosage when given by mouth to patients with cirrhosis of the liver.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D002719:Chlormethiazole / Q000008:administration & dosage / Q000378:metabolism*; D005167:Factor VII / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D008104:Liver Cirrhosis, Alcoholic / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged
D002719:Chlormethiazole; D005167:Factor VII